drugset / Trial / NCT00683267

Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

NCT00683267

Phase 2 Terminated 118 enrolled Anesiva, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the efficacy, safety and tolerability of a single intraoperative dose of 4975 in patients undergoing total hip replacement

Timeline

Start
2007-09
Primary completion
2008-11
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule Other

Indications

No indication recorded.